Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum Berlin, Germany, May 7, 2026 – Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), a clinical-stage biotech company developing novel radiopharmaceuticals, today reported financial results for the first quarter ended March 31, 2026, and provided  [ … ]

  Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program U.S. Investigational New Drug (IND) applications for radiotheranostic pair PentixaFor and PentixaTher became active following completion of the FDA 30-day review period. Proposed phase I/II trial designed to confirm the suitab [ … ]

Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism •   In the study, [68Ga]Ga-Pentixafor PET/CT was well tolerated and demonstrated high specificity and moderate sensitivity for identifying unilateral aldosterone-producing adenomas compared with adrenal vein  [ … ]